ArticleJournal of neuro-oncology2026
Biological aging enhances prognostic stratification beyond chronological age in breast cancer brain metastases.
Article in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Current breast cancer–specific graded prognostic assessment (GPA) models primarily rely on chronological age and clinical disease characteristics, which may inadequately reflect inter-individual vulnerability and physiological reserve. We investigated whether phenotypic biological aging, quantified by PhenoAgeAccel, provides prognostic information beyond chronological age in patients with breast cancer brain metastases (BCBM) and whether integration of biological aging improves the performance of established Breast-GPA models. Methods: We retrospectively analyzed 432 consecutive patients with BCBM. Overall survival (OS) was measured from brain metastasis diagnosis. Biological aging was assessed using PhenoAgeAccel derived from routinely available laboratory parameters. Multivariable Cox models evaluated independent prognostic factors, with primary analyses in patients with parenchymal brain metastases. Original and PhenoAge-modified Breast-GPA scores were compared using Harrell’s C-index and milestone survival analyses (3 and 36 months). Results: Median OS for the overall cohort was 8.7 months (95% CI 7.4–10.1). Accelerated biological aging (PhenoAgeAccel > 0) was observed in 39.8% of evaluable patients (n = 294) and was associated with significantly shorter OS (median 4.4 vs. 14.6 months; p < 0.001). In multivariable analyses, PhenoAgeAccel remained independently associated with mortality (HR 1.88, 95% CI 1.44–2.46; p < 0.001), whereas chronological age was not. Similar findings were observed in patients with parenchymal brain metastases (HR 1.83, 95% CI 1.35–2.48; p < 0.001). Adding biological aging improved discrimination of Breast-GPA models (C-index up to ~ 0.71) and strengthened prediction of early (3-month) and long-term (36-month) survival status. Conclusions: Phenotypic biological aging provides prognostic information beyond chronological age in BCBM and strengthens established GPA-based risk stratification. Integration of biological aging metrics may support more individualized prognostic assessment in clinical practice.
Indexed as
Identifiers
41774307What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.